The Valley Desk

Clinical trial reportThyroid : official journal of the American Thyroid AssociationPublished

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Thyroid : official journal of the American Thyroid Association
Published
Subject terms
Humans; Adenocarcinoma; Thyroid Neoplasms; Iodine Radioisotopes; Anilides; Phenylurea Compounds; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Antineoplastic Agents; Protein Kinase Inhibitors
PubMed ID
38062732
PubMed Central ID
PMC10951569
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal